• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Insulin zinc suspension compared with crystalline insulin zinc suspension

StudyPopulationInterventionOutcomesResultsCommentsDesignEL
Johnson et al, 199220677 children and young people with type 1 diabetes
Aged 5–18 years
USA
Twice-daily use of crystalline insulin zinc suspension with soluble insulin
versus
twice-daily use of insulin zinc suspension with soluble insulin
Trial length: 12 weeks
  1. HbA1 level
  2. Fasting blood glucose
  1. 8.5 ± 0.3% vs. 8.1 ± 0.2%, no statistical difference
  2. Pre-lunch: no statistical difference, pre- dinner: no statistical difference, bedtime: no statistical difference, mid-sleep: no statistical difference
    pre-breakfast: 10.6 ± 0.6 vs.
    12.6 ± 0.6 mmol/l, p < 0.02
No description of how randomisation took place
Supported by Eli Lilly
RCT parallelIb
Turnbridge et al, 1989 20766 adults with type 1 diabetes
Aged 18–62, mean age 38 years
UK
Twice-daily use of crystalline insulin zinc suspension with soluble insulin
versus
twice-daily use of insulin zinc suspension with soluble insulin
Trial length: two 3-month periods
  1. Glycated haemoglobin levels
  2. Fasting blood glucose levels
  3. Serious hypoglycaemic events
  1. The trial found no difference between the two groups: 9.3 ± 0.2%
  2. 6.6 ± 0.5 vs. 8.2 ± 0.5 mmol/l, p < 0.05
  3. 0.38 ± 0.10 vs. 0.09 ± 0.04 events per patient per month, p < 0.02
No description of how randomisation took place
Supported by Novo Laboratories
RCT crossoverIb

From: Evidence tables

Cover of Type 1 Diabetes
Type 1 Diabetes: Diagnosis and Management of Type 1 Diabetes in Children and Young People.
NICE Clinical Guidelines, No. 15.2.
National Collaborating Centre for Women's and Children's Health (UK).
London: RCOG Press; 2004 Sep.
Copyright © 2004, National Collaborating Centre for Women’s and Children’s Health.

Apart from any fair dealing for the purposes of research or private study, criticism or review, as permitted under the Copyright, Designs and Patents Act, 1988, no part of this publication may be reproduced, stored or transmitted in any form or by any means, without the prior written permission of the publisher or, in the case of reprographic reproduction, in accordance with the terms of licences issued by the Copyright Licensing Agency in the UK. Enquiries concerning reproduction outside the terms stated here should be sent to the publisher at the UK address printed on this page.

The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant laws and regulations and therefore for general use.

The rights of National Collaborating Centre for Women’s and Children’s Health to be identified as Author of this work have been asserted by them in accordance with the Copyright, Designs and Patents Act, 1988.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.